Skip to main content
. 2019 Aug 23;30(11):2140–2157. doi: 10.1681/ASN.2019030236

Figure 4.

Figure 4.

MPO/BAY DCs do not inhibit immunity against an irrelevant antigen. (A) Experimental design. MPO/BAY DCs (n=4) or saline (n=4) were administered to mice with established anti-mBSA immunity (day 14), 7 days before triggering GN, and experiments ended on day 26. (B) Dermal DTH (change in skin swelling between mBSA and saline-injected footpads). (C–E) T cell and B cell responses, assessed by flow cytometry using mBSA-restimulated LN cells. (C) CD4 T cell proliferation, apoptosis (AnV+PI−), and activation (CD44), and the proportion of CD4 T cells expressing IL-17A, IFNγ, or IL-4. (D) CD8 T cell proliferation, apoptosis, and CD44 expression, and the proportion of CD8 T cells producing IL-17A, IFNγ, or IL-4. (E) B cell proliferation and apoptosis. (F) Total serum anti-mBSA IgG levels (ELISA). (G) The proportion of abnormal glomeruli. Data are presented as scatter plots with the mean±SEM. *P<0.05. nms, normal mouse serum. CFA, Complete Freund Adjuvant; IFA, Incomplete Freund Adjuvant.